A hedge fund manager with a 9.5% stake in Inamed Corp. said Thursday it hadn’t decided whether to support Allergan Inc.’s $3.2 billion offer for the company.
SAC Capital Advisors, a $6 billion hedge fund manager, said in a regulatory filing that it’s “reviewing” Allergan’s offer.
The Irvine drug maker made its offer for Santa Barbara-based Inamed, a medical products and device maker, for about $84 a share last month.
Scottsdale-based Medicis Pharmaceutical Corp. has made a previous offer to buy Inamed for $2.5 billion. Inamed said earlier this week that the Allergan offer was “superior,” allowing it to end the previous agreement with Medicis.
Allergan’s shares closed up 1.07% to $108 on Thursday.
